Dec. 9, 2023

David Sanders and Tony Paquin-Securing America's Pharmaceutical Supply

In this episode of Life Science Success, we are talking about Securing America's Pharmaceutical Supply with David Sanders and Tony Paquin.  We are going to discuss derisking the supply chain and building resilience.   Don, is joined by...

In this episode of Life Science Success, we are talking about Securing America's Pharmaceutical Supply with David Sanders and Tony Paquin.  We are going to discuss derisking the supply chain and building resilience.

 

Don, is joined by guests, David Sanders and Tony Paquin. They discuss the importance and challenges of securing America's medical supply chain. David introduces himself as the Vice President of Government Affairs at Coherence Biosciences and Executive Director at Securing America's Medicine and Supply, and Tony as the CEO and co-founder of iRemedy Healthcare, an AI-driven supply chain platform. They delve into the impacts of the COVID-19 pandemic on these supply chains, their effort in repatriating pharmaceutical supply and manufacturing back in America, and the role of innovation in overcoming the costs and barriers involved. Tony also mentioned his book, "The End of Us," which talks about this same issue.

Please check out our Life Science Success Resources.  You will find tools that will support growing companies and books for authors I have interviewed.  

David T. SandersProfile Photo

David T. Sanders

SAMS Executive Director Vice President, Government Affairs and Policy, Coherus BioSciences

David Sanders has more than twenty years of experience working in government and industry. He worked for Senator Fred Thompson (R-TN), then-Representative Marsha Blackburn (R-TN), and Bush-Cheney 2004. He served as a legislative liaison for the U.S. Patent and Trademark Office, working on intellectual property and trade law. He advanced policy working for Teva Pharmaceuticals USA, National Community Pharmacists Association and DaVita Inc. before joining Coherus BioSciences in the summer of 2020 where he leads a small team in policy, advocacy and public affairs.